De Novo KRAS G12C–Mutant SCLC: A Case Report

The application of KRAS G12C inhibitors in the setting of NSCLC represents a major milestone for a previously “undruggable” target. Here, we present the second reported case of de novo KRAS G12C–mutant primary SCLC. Would our patient benefit from a KRAS G12C inhibitor?

Saved in:
Bibliographic Details
Published in:JTO clinical and research reports 2022-05, Vol.3 (5), p.100306, Article 100306
Main Authors: Balbach, Meridith L., Eisenberg, Rosana, Iams, Wade T.
Format: Article
Language:English
Subjects:
Case Report
KRAS G12C
Small cell lung cancer
Targeted therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c399t-5521256a520f300aa3124249b3d94940d43c3e3bbe5d0c68af3ef8a101026bfe3
container_end_page
container_issue 5
container_start_page 100306
container_title JTO clinical and research reports
container_volume 3
creator Balbach, Meridith L.
Eisenberg, Rosana
Iams, Wade T.
description The application of KRAS G12C inhibitors in the setting of NSCLC represents a major milestone for a previously “undruggable” target. Here, we present the second reported case of de novo KRAS G12C–mutant primary SCLC. Would our patient benefit from a KRAS G12C inhibitor?
doi_str_mv 10.1016/j.jtocrr.2022.100306
format article
fullrecord <record><control><sourceid>pubmed_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_4621a2e73c024969b5fb643102abe0f2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2666364322000303</els_id><doaj_id>oai_doaj_org_article_4621a2e73c024969b5fb643102abe0f2</doaj_id><sourcerecordid>35434667</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-5521256a520f300aa3124249b3d94940d43c3e3bbe5d0c68af3ef8a101026bfe3</originalsourceid><addsrcrecordid>eNp9kd1OwkAQhTdGIwR5A2P6AuDsTxfqhQmpikTUBPR6s91OsQ2wZFtIvPMdfEOfxMUqyo1Xu5nJfGfOHEJOKXQpUHledIvKGue6DBjzJeAgD0iTSSk7XAp--OffIO2yLACAhZT2-uyYNHgouJCy1yTdKwwe7MYGd5PBNBhSFn-8vd-vK72sgmk8ji-CQRDrEoMJrqyrTshRpucltr_fFnm-uX6Kbzvjx-EoHow7hkdR1QlDRlkodcgg4wBac8oEE1HC00hEAlLBDUeeJBimYGRfZxyzvvbWgMkkQ94io5qbWl2olcsX2r0qq3P1VbBuprSrcjNHJSSjmmGPG_AKMkrCLPGuPUknCBnzrMuatVonC0wNLiun53vQ_c4yf1Ezu1GRX0dy8ABRA4yzZekw281SUNs4VKHqONQ2DlXH4cfO_uruhn6O_7sY-ktucnSqNDkuDaa5Q1N5q_n_Cp98opo7</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>De Novo KRAS G12C–Mutant SCLC: A Case Report</title><source>ScienceDirect Journals</source><source>PubMed Central</source><creator>Balbach, Meridith L. ; Eisenberg, Rosana ; Iams, Wade T.</creator><creatorcontrib>Balbach, Meridith L. ; Eisenberg, Rosana ; Iams, Wade T.</creatorcontrib><description>The application of KRAS G12C inhibitors in the setting of NSCLC represents a major milestone for a previously “undruggable” target. Here, we present the second reported case of de novo KRAS G12C–mutant primary SCLC. Would our patient benefit from a KRAS G12C inhibitor?</description><identifier>ISSN: 2666-3643</identifier><identifier>EISSN: 2666-3643</identifier><identifier>DOI: 10.1016/j.jtocrr.2022.100306</identifier><identifier>PMID: 35434667</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Case Report ; KRAS G12C ; Small cell lung cancer ; Targeted therapy</subject><ispartof>JTO clinical and research reports, 2022-05, Vol.3 (5), p.100306, Article 100306</ispartof><rights>2022 The Authors</rights><rights>2022 The Authors.</rights><rights>2022 The Authors 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c399t-5521256a520f300aa3124249b3d94940d43c3e3bbe5d0c68af3ef8a101026bfe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010630/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2666364322000303$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,3536,27901,27902,45756,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35434667$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Balbach, Meridith L.</creatorcontrib><creatorcontrib>Eisenberg, Rosana</creatorcontrib><creatorcontrib>Iams, Wade T.</creatorcontrib><title>De Novo KRAS G12C–Mutant SCLC: A Case Report</title><title>JTO clinical and research reports</title><addtitle>JTO Clin Res Rep</addtitle><description>The application of KRAS G12C inhibitors in the setting of NSCLC represents a major milestone for a previously “undruggable” target. Here, we present the second reported case of de novo KRAS G12C–mutant primary SCLC. Would our patient benefit from a KRAS G12C inhibitor?</description><subject>Case Report</subject><subject>KRAS G12C</subject><subject>Small cell lung cancer</subject><subject>Targeted therapy</subject><issn>2666-3643</issn><issn>2666-3643</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9kd1OwkAQhTdGIwR5A2P6AuDsTxfqhQmpikTUBPR6s91OsQ2wZFtIvPMdfEOfxMUqyo1Xu5nJfGfOHEJOKXQpUHledIvKGue6DBjzJeAgD0iTSSk7XAp--OffIO2yLACAhZT2-uyYNHgouJCy1yTdKwwe7MYGd5PBNBhSFn-8vd-vK72sgmk8ji-CQRDrEoMJrqyrTshRpucltr_fFnm-uX6Kbzvjx-EoHow7hkdR1QlDRlkodcgg4wBac8oEE1HC00hEAlLBDUeeJBimYGRfZxyzvvbWgMkkQ94io5qbWl2olcsX2r0qq3P1VbBuprSrcjNHJSSjmmGPG_AKMkrCLPGuPUknCBnzrMuatVonC0wNLiun53vQ_c4yf1Ezu1GRX0dy8ABRA4yzZekw281SUNs4VKHqONQ2DlXH4cfO_uruhn6O_7sY-ktucnSqNDkuDaa5Q1N5q_n_Cp98opo7</recordid><startdate>20220501</startdate><enddate>20220501</enddate><creator>Balbach, Meridith L.</creator><creator>Eisenberg, Rosana</creator><creator>Iams, Wade T.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20220501</creationdate><title>De Novo KRAS G12C–Mutant SCLC: A Case Report</title><author>Balbach, Meridith L. ; Eisenberg, Rosana ; Iams, Wade T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-5521256a520f300aa3124249b3d94940d43c3e3bbe5d0c68af3ef8a101026bfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Case Report</topic><topic>KRAS G12C</topic><topic>Small cell lung cancer</topic><topic>Targeted therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Balbach, Meridith L.</creatorcontrib><creatorcontrib>Eisenberg, Rosana</creatorcontrib><creatorcontrib>Iams, Wade T.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>JTO clinical and research reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Balbach, Meridith L.</au><au>Eisenberg, Rosana</au><au>Iams, Wade T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>De Novo KRAS G12C–Mutant SCLC: A Case Report</atitle><jtitle>JTO clinical and research reports</jtitle><addtitle>JTO Clin Res Rep</addtitle><date>2022-05-01</date><risdate>2022</risdate><volume>3</volume><issue>5</issue><spage>100306</spage><pages>100306-</pages><artnum>100306</artnum><issn>2666-3643</issn><eissn>2666-3643</eissn><abstract>The application of KRAS G12C inhibitors in the setting of NSCLC represents a major milestone for a previously “undruggable” target. Here, we present the second reported case of de novo KRAS G12C–mutant primary SCLC. Would our patient benefit from a KRAS G12C inhibitor?</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35434667</pmid><doi>10.1016/j.jtocrr.2022.100306</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2666-3643
ispartof JTO clinical and research reports, 2022-05, Vol.3 (5), p.100306, Article 100306
issn 2666-3643
2666-3643
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_4621a2e73c024969b5fb643102abe0f2
source ScienceDirect Journals; PubMed Central
subjects Case Report
KRAS G12C
Small cell lung cancer
Targeted therapy
title De Novo KRAS G12C–Mutant SCLC: A Case Report
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T04%3A08%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=De%20Novo%20KRAS%20G12C%E2%80%93Mutant%20SCLC:%20A%20Case%20Report&rft.jtitle=JTO%20clinical%20and%20research%20reports&rft.au=Balbach,%20Meridith%20L.&rft.date=2022-05-01&rft.volume=3&rft.issue=5&rft.spage=100306&rft.pages=100306-&rft.artnum=100306&rft.issn=2666-3643&rft.eissn=2666-3643&rft_id=info:doi/10.1016/j.jtocrr.2022.100306&rft_dat=%3Cpubmed_doaj_%3E35434667%3C/pubmed_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c399t-5521256a520f300aa3124249b3d94940d43c3e3bbe5d0c68af3ef8a101026bfe3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/35434667&rfr_iscdi=true